ANALYSIS OF THE WORK OF A MULTIDISCIPLINARY GROUP IN THE TREATMENT OF LUNG CANCER IN THE TURKESTAN REGION FOR 2019-2020
Introduction: The introduction of a multidisciplinary approach to the treatment of lung cancer has now become very much in demand, since the precise determination of the molecular and biological characteristics of the tumor, before the start of treatment, allows for a significant improvement in the results of increasing overall and relapse-free survival.
The aim of the study is to analyze the performance of a multidisciplinary group in the treatment of lung cancer and to study mutations in the EGFR, ALK gene in the Turkestan region for 2019-2020.
Materials and methods: The study is a retrospective observational one. An analysis was made of the performance indicators of a multidisciplinary group working on the basis of the oncological center of the Turkestan region for 2019-2020.During the study period, 391 patients were examined by a multidisciplinary group. The analyzed indicators were: patient's age, gender, histological data, diagnosis, stages, types of treatment.
All statistical calculations were performed using the SPSS program (version 25.0, IBM SPSS Inc., Chicago, USA).The data were summarized using descriptive statistics methods.
Statistical processing of the obtained data was carried out using Microsoft Excel, the average value was determined. The data were summarized using descriptive statistics methods.
Results: The largest number of patients with lung cancer were referred for combined treatment, palliative chemotherapy, targeted therapy. In 2020, compared to 2019, the percentage of combination therapy increased by 3%, and the percentage of targeted therapy increased by 4%. Mutations of the EGFR gene were detected, of which Ex19del, L858R, Ex20Ins, T790M were detected.
Conclusion: For the first time, an analysis of the work of MDG in the treatment of lung cancer in the Turkestan region for 2019-2020 was carried out. Improved diagnostics of indicators of molecular genetic studies in the EGFR gene, ALK-positive metastatic non-small cell lung cancer, which made it possible to optimize the choice of personalized treatment tactics for patients and refer them to combined treatment, palliative chemotherapy and targeted therapy, which reduced the number of registrations of new cases of advanced lung cancer.
Zhanar S. Tumenbayeva1, https://orcid.org/0009-0004-9104-8954
South Kazakhstan Medical Academy,
Shymkent, Republic of Kazakhstan
1. Кайдарова Д.Р., Балтабекова Н.Т., Душимова З.Д. и др. Показатели онкологической службы Республики Казахстан за 2019 – 09.02.2021 годы (статистические и аналитические материалы), Almaty. https://onco.kz/Pokazateli-onkologicheskoj-sluzhby-Respubliki-Kazahstan-za-2019-g_09.02.2021_compressed-1.pdf. (Дата обращения 01.04.2023)
2. Bailey-Wilson J.E., Amos C.I., Pinney S.M. et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. // J Hum Genet 2004. 75(3):460–474.
3. City J., Buffett P. What proportion of lung cancer in non-smokers can be attributed to known risk factors? // Int J Cancer. 2012. 131 (2): 265–275. DOI: 10.1002 / ijc.27477
4. El Тelbani A., Ma P.C. Cancer genes in lung cancer: racial differences: are there? // Cancer genes. 2012. 3 (7–8): 467–480. DOI: 10.1177 / 1947601912465177
5. Fujikawa A., Takiguchi Y., Mizuno S., et al. Lung cancer screening - comparison of computed tomography and radiography // Lung cancer. 2008. 61 (2): 195–201. DOI: 10.1016 / j. lungcan.2007.12.010
6. Goldstraw P., Ball D., Jett J.R. et al. Non-small-cell lung cancer // Lancet, 2011. 378: 1727–40.
7. Greenhalgh J., Boland A., Bates V., Vecchio F., Dundar Y., Chaplin M., Green J.A. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer // Cochrane Database Syst Rev. 2021 Mar 1. 3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3.
8. Janne P.A.,Yang J.S., Kim D.W. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer // N Engl J Med. 2015. 372:1700-1709.
9. Kang H.R., ChOj.Y., Li Sh. et al. The role of low-dose computed tomography in screening for lung cancer in non-smokers // J Thorac Oncol. 2019; 14 (3): 436–444. DOI: 10.1016 / j. jtho.2018.11.002
10. Lin L., Li Z., Yan L., Liu Y., Yang H., Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019 // J Hematol Oncol. 2021 Nov. 22. 14(1):197. doi: 10.1186/s13045-021-01213-z.
11. Mendelson J., aselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer //Journal Clinical Oncology. 2003. Vol.21. P.2787-99.
12. Midcha A., Dirden S., McCormack R. Prevalence of EGFR mutation in non-small cell lung cancer in adenocarcinoma histology: a systematic review and a global map by ethnicity (mutMapII) // J Cancer Res. 2015. 5 (9): 2892–2911.
13. Mok T.S., Wu Y, Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl // J Med 2009; 361: 947–957.
14. Murray S., Dahabreh I.J., Linardou H., et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non small cell lung cancer:an analytical database // J Thorac Oncol. 2008. 3:832-839.
15. Planchard D., Popat S., Kerr K. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. 2018. 29(Suppl 5): iv192–iv237.
16. Sun Y., Ren Y., Fang Z. et al. Lung adenocarcinoma in never-smokers from East Asia is a disease largely determined by guided oncogenic mutant kinases. // J Clin Oncol. 2010. 28 (30): 4616–4620. DOI: 10.1200 / JCO.2010.29.6038
17. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J. Clin. 2021: 71: 209-249. https://doi.org/10.3322/caac.21660
18. Timofeeva M.N., Hung J., Rafnar T. et al. The effect of common genetic variations on lung cancer risk: meta-analysis of 14,900 cases and 29,485 controls // Hum Mol Genet. 2012. 21 (22): 4980-4995. DOI: 10.1093/hmg/dds334
19. Torre L.A., Bray F., Siegel R.L. et al. Global cancer statistics, 2012 // CA Cancer J Clin. 2015. 65:87–108.
20. Yang V., Qian F, Teng J, et al. Community-based lung cancer screening with low-dose CT in China: results of basic screening // Lung cancer. 2018. 117: 20–26. DOI: 10.1016 / j. lungcan.2018.01.003
21. Yang J.C., Sequist L.V., Geater S.L. et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 // Lancet Oncol. 2015. Vol.7. №16. P. 830-838.
References: [1]
1. Kaidarova D.R., Baltabekova N.T., Dushimova Z.D. i dr. Pokazateli onkologicheskoi sluzhby Respubliki Kazakhstan za 2019-09.02.2021 gody (statisticheskie i analiticheskie materialy) [Indicators of the oncological service of the Republic of Kazakhstan for 2019 - 09.02.2021 (statistical and analytical materials)], Almaty. https://Pokazateli-onkologicheskoj-sluzhby-Respubliki-Kazahstan-za-2019-g_09.02.2021_compressed-1.pdf (accessed 01.04.2023)
Number of Views: 52
Category of articles:
Original articles
Bibliography link
Tumenbayeva Zh.S. Analysis of the work of a multidisciplinary group in the treatment of lung cancer in the Turkestan region for 2019-2020 // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 3, pp. 101-107. doi 10.34689/SH.2023.25.3.013Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS